These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37503487)

  • 21. Epidemiology of Nontuberculous Mycobacteria in Nanjing and
    Zhang R; Luo S; Wang N; Zhang H; Wu X
    Infect Drug Resist; 2023; 16():2751-2764. PubMed ID: 37180636
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Susceptibility to Injectable Antibiotics on the Treatment Outcomes of
    Park Y; Park YE; Jhun BW; Park J; Kwak N; Jo KW; Yim JJ; Shim TS; Kang YA
    Open Forum Infect Dis; 2021 Jun; 8(6):ofab215. PubMed ID: 34189168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clofazimine in
    Pinapala A; Koh LJ; Ng KH; Tambyah PA; Yap HK
    Perit Dial Int; 2021 Jan; 41(1):104-109. PubMed ID: 32148178
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bactericidal and intracellular activity of β-lactams against Mycobacterium abscessus.
    Lefebvre AL; Dubée V; Cortes M; Dorchêne D; Arthur M; Mainardi JL
    J Antimicrob Chemother; 2016 Jun; 71(6):1556-63. PubMed ID: 26929268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic Efficacy of β-Lactam Combinations against
    Story-Roller E; Maggioncalda EC; Lamichhane G
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31109979
    [No Abstract]   [Full Text] [Related]  

  • 26. Dual β-lactams for the treatment of Mycobacterium abscessus: a review of the evidence and a call to act against an antibiotic nightmare.
    Longo BM; Trunfio M; Calcagno A
    J Antimicrob Chemother; 2024 Aug; ():. PubMed ID: 39150384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. β-Lactam Combinations That Exhibit Synergy against Mycobacteroides abscessus Clinical Isolates.
    Story-Roller E; Galanis C; Lamichhane G
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33361310
    [No Abstract]   [Full Text] [Related]  

  • 28. Diagnosis and Management of Pulmonary NTM with a Focus on
    Hendrix C; McCrary M; Hou R; Abate G
    Microorganisms; 2022 Dec; 11(1):. PubMed ID: 36677340
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Beech AJ; Weinberg SE; Mortimer AE; Lynch F; Bedford J; Calisti G
    J Clin Tuberc Other Mycobact Dis; 2023 Aug; 32():100381. PubMed ID: 37323244
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of broad-spectrum Mycobacterium abscessus class A β-lactamase.
    Soroka D; Dubée V; Soulier-Escrihuela O; Cuinet G; Hugonnet JE; Gutmann L; Mainardi JL; Arthur M
    J Antimicrob Chemother; 2014 Mar; 69(3):691-6. PubMed ID: 24132992
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of two-drug combinations, amikacin/tigecycline/imipenem and amikacin/tigecycline/clarithromycin against Mycobacteroides abscessus subsp. abscessus using the in vitro time-kill assay.
    Portell-Buj E; Bonet-Rossinyol Q; López-Gavín A; Roman A; Fernández-Pittol M; Tudó G; Gonzalez-Martin J
    J Antibiot (Tokyo); 2021 Apr; 74(4):285-290. PubMed ID: 33420382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lack of adherence to evidence-based treatment guidelines for nontuberculous mycobacterial lung disease.
    Adjemian J; Prevots DR; Gallagher J; Heap K; Gupta R; Griffith D
    Ann Am Thorac Soc; 2014 Jan; 11(1):9-16. PubMed ID: 24236749
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Amoxicillin in combination with Imipenem-Relebactam against Mycobacterium abscessus.
    Lopeman RC; Harrison J; Rathbone DL; Desai M; Lambert PA; Cox JAG
    Sci Rep; 2020 Jan; 10(1):928. PubMed ID: 31988293
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Shen Y; Wang X; Jin J; Wu J; Zhang X; Chen J; Zhang W
    Biomed Res Int; 2018; 2018():4902941. PubMed ID: 30687747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. β-Lactamase inhibition by avibactam in Mycobacterium abscessus.
    Dubée V; Bernut A; Cortes M; Lesne T; Dorchene D; Lefebvre AL; Hugonnet JE; Gutmann L; Mainardi JL; Herrmann JL; Gaillard JL; Kremer L; Arthur M
    J Antimicrob Chemother; 2015 Apr; 70(4):1051-8. PubMed ID: 25525201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In Vitro Antimicrobial Susceptibility of Nontuberculous Mycobacteria in Iran.
    Heidarieh P; Mirsaeidi M; Hashemzadeh M; Feizabadi MM; Bostanabad SZ; Nobar MG; Hashemi Shahraki A
    Microb Drug Resist; 2016 Mar; 22(2):172-8. PubMed ID: 26468990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection.
    Negatu DA; González Del Río R; Cacho-Izquierdo M; Barros-Aguirre D; Lelievre J; Rullas J; Casado P; Ganapathy US; Zimmerman MD; Gengenbacher M; Dartois V; Dick T
    Antimicrob Agents Chemother; 2023 Feb; 67(2):e0145922. PubMed ID: 36688684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contemporary Pharmacotherapies for Nontuberculosis Mycobacterial Infections: A Narrative Review.
    Johnson TM; Byrd TF; Drummond WK; Childs-Kean LM; Mahoney MV; Pearson JC; Rivera CG
    Infect Dis Ther; 2023 Feb; 12(2):343-365. PubMed ID: 36609820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of Mycobacterium abscessus Pulmonary Disease.
    Griffith DE; Daley CL
    Chest; 2022 Jan; 161(1):64-75. PubMed ID: 34314673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evolution towards extremely high β-lactam resistance in
    le Run E; Tettelin H; Holland SM; Zelazny AM
    bioRxiv; 2024 May; ():. PubMed ID: 38903073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.